253 related articles for article (PubMed ID: 27853369)
21. Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting.
Song S; Qi H; Xu J; Guo P; Chen F; Li F; Yang X; Sheng N; Wu Y; Pan W
Pharm Res; 2014 Nov; 31(11):2988-3005. PubMed ID: 24842660
[TBL] [Abstract][Full Text] [Related]
22. CD44-Targeted Facile Enzymatic Activatable Chitosan Nanoparticles for Efficient Antitumor Therapy and Reversal of Multidrug Resistance.
Zhang X; He F; Xiang K; Zhang J; Xu M; Long P; Su H; Gan Z; Yu Q
Biomacromolecules; 2018 Mar; 19(3):883-895. PubMed ID: 29401378
[TBL] [Abstract][Full Text] [Related]
23. pH- and GSH-Sensitive Hyaluronic Acid-MP Conjugate Micelles for Intracellular Delivery of Doxorubicin to Colon Cancer Cells and Cancer Stem Cells.
Debele TA; Yu LY; Yang CS; Shen YA; Lo CL
Biomacromolecules; 2018 Sep; 19(9):3725-3737. PubMed ID: 30044910
[TBL] [Abstract][Full Text] [Related]
24. Free Adriamycin-Loaded pH/Reduction Dual-Responsive Hyaluronic Acid-Adriamycin Prodrug Micelles for Efficient Cancer Therapy.
Yin T; Wang Y; Chu X; Fu Y; Wang L; Zhou J; Tang X; Liu J; Huo M
ACS Appl Mater Interfaces; 2018 Oct; 10(42):35693-35704. PubMed ID: 30259743
[TBL] [Abstract][Full Text] [Related]
25. Dual Receptor-Targeted and Redox-Sensitive Polymeric Micelles Self-Assembled from a Folic Acid-Hyaluronic Acid-SS-Vitamin E Succinate Polymer for Precise Cancer Therapy.
Yang Y; Li Y; Chen K; Zhang L; Qiao S; Tan G; Chen F; Pan W
Int J Nanomedicine; 2020; 15():2885-2902. PubMed ID: 32425522
[TBL] [Abstract][Full Text] [Related]
26. GE11 peptide modified and reduction-responsive hyaluronic acid-based nanoparticles induced higher efficacy of doxorubicin for breast carcinoma therapy.
Hu D; Mezghrani O; Zhang L; Chen Y; Ke X; Ci T
Int J Nanomedicine; 2016; 11():5125-5147. PubMed ID: 27785019
[TBL] [Abstract][Full Text] [Related]
27. Mulberry-like dual-drug complicated nanocarriers assembled with apogossypolone amphiphilic starch micelles and doxorubicin hyaluronic acid nanoparticles for tumor combination and targeted therapy.
Li K; Liu H; Gao W; Chen M; Zeng Y; Liu J; Xu L; Wu D
Biomaterials; 2015 Jan; 39():131-44. PubMed ID: 25477180
[TBL] [Abstract][Full Text] [Related]
28. Combination Therapy of Doxorubicin and Quercetin on Multidrug-Resistant Breast Cancer and Their Sequential Delivery by Reduction-Sensitive Hyaluronic Acid-Based Conjugate/d-α-Tocopheryl Poly(ethylene glycol) 1000 Succinate Mixed Micelles.
Liu S; Li R; Qian J; Sun J; Li G; Shen J; Xie Y
Mol Pharm; 2020 Apr; 17(4):1415-1427. PubMed ID: 32159961
[TBL] [Abstract][Full Text] [Related]
29. Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.
Liu HN; Guo NN; Wang TT; Guo WW; Lin MT; Huang-Fu MY; Vakili MR; Xu WH; Chen JJ; Wei QC; Han M; Lavasanifar A; Gao JQ
Mol Pharm; 2018 Mar; 15(3):882-891. PubMed ID: 29357260
[TBL] [Abstract][Full Text] [Related]
30. Hyaluronic acid modified pH-sensitive liposomes for targeted intracellular delivery of doxorubicin.
Paliwal SR; Paliwal R; Agrawal GP; Vyas SP
J Liposome Res; 2016 Dec; 26(4):276-87. PubMed ID: 26784587
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel delivered by CD44 receptor-targeting and endosomal pH sensitive dual functionalized hyaluronic acid micelles for multidrug resistance reversion.
Liu Y; Zhou C; Wei S; Yang T; Lan Y; Cao A; Yang J; Hou Y
Colloids Surf B Biointerfaces; 2018 Oct; 170():330-340. PubMed ID: 29936386
[TBL] [Abstract][Full Text] [Related]
32. Dual pH-responsive multifunctional nanoparticles for targeted treatment of breast cancer by combining immunotherapy and chemotherapy.
Liu Y; Qiao L; Zhang S; Wan G; Chen B; Zhou P; Zhang N; Wang Y
Acta Biomater; 2018 Jan; 66():310-324. PubMed ID: 29129789
[TBL] [Abstract][Full Text] [Related]
33. Overcoming multidrug resistance by intracellular drug release and inhibiting p-glycoprotein efflux in breast cancer.
Mao J; Qiu L; Ge L; Zhou J; Ji Q; Yang Y; Long M; Wang D; Teng L; Chen J
Biomed Pharmacother; 2021 Feb; 134():111108. PubMed ID: 33341670
[TBL] [Abstract][Full Text] [Related]
34. Reversal of doxorubicin resistance in breast cancer by mitochondria-targeted pH-responsive micelles.
Yu P; Yu H; Guo C; Cui Z; Chen X; Yin Q; Zhang P; Yang X; Cui H; Li Y
Acta Biomater; 2015 Mar; 14():115-24. PubMed ID: 25498306
[TBL] [Abstract][Full Text] [Related]
35. Stealth CD44-targeted hyaluronic acid supramolecular nanoassemblies for doxorubicin delivery: probing the effect of uncovalent pegylation degree on cellular uptake and blood long circulation.
Han X; Li Z; Sun J; Luo C; Li L; Liu Y; Du Y; Qiu S; Ai X; Wu C; Lian H; He Z
J Control Release; 2015 Jan; 197():29-40. PubMed ID: 25449802
[TBL] [Abstract][Full Text] [Related]
36. An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance.
Lu J; Zhao W; Liu H; Marquez R; Huang Y; Zhang Y; Li J; Xie W; Venkataramanan R; Xu L; Li S
J Control Release; 2014 Dec; 196():272-86. PubMed ID: 25456831
[TBL] [Abstract][Full Text] [Related]
37. Doxorubicin-loaded redox-responsive micelles based on dextran and indomethacin for resistant breast cancer.
Zhou Y; Wang S; Ying X; Wang Y; Geng P; Deng A; Yu Z
Int J Nanomedicine; 2017; 12():6153-6168. PubMed ID: 28883726
[TBL] [Abstract][Full Text] [Related]
38. A pH-sensitive prodrug strategy to co-deliver DOX and TOS in TPGS nanomicelles for tumor therapy.
Xiong S; Wang Z; Liu J; Deng X; Xiong R; Cao X; Xie Z; Lei X; Chen Y; Tang G
Colloids Surf B Biointerfaces; 2019 Jan; 173():346-355. PubMed ID: 30316081
[TBL] [Abstract][Full Text] [Related]
39. Robust, active tumor-targeting and fast bioresponsive anticancer nanotherapeutics based on natural endogenous materials.
Sun B; Deng C; Meng F; Zhang J; Zhong Z
Acta Biomater; 2016 Nov; 45():223-233. PubMed ID: 27576338
[TBL] [Abstract][Full Text] [Related]
40. Self-assembling doxorubicin-tocopherol succinate prodrug as a new drug delivery system: synthesis, characterization, and in vitro and in vivo anticancer activity.
Duhem N; Danhier F; Pourcelle V; Schumers JM; Bertrand O; Leduff CS; Hoeppener S; Schubert US; Gohy JF; Marchand-Brynaert J; Préat V
Bioconjug Chem; 2014 Jan; 25(1):72-81. PubMed ID: 24328289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
